Mituo Suo (米托索)米托索
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 浙江万联药业有限公司Chinese legal name: 浙江万联药业有限公司
主要成分Active Ingredients
- 甲地孕酮Jiadi Yuntong
药物知识说明
甲地孕酮是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括：甲地孕酮Jiadi Yuntong。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品：甲地孕酮-02dc6577成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 米托索) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Active ingredients associated with this product: 甲地孕酮Jiadi Yuntong.
Explore other medicines containing the same ingredient: 甲地孕酮 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 米托索Recorded Chinese name: 米托索
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 40mg*32粒40 mg × 32 capsules
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 浙江万联药业有限公司Chinese legal name: 浙江万联药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20020242
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20020242
Manufacturer
Chinese legal name: 浙江万联药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
40 mg × 32 capsules
中文说明书原文Original Chinese source label
批准文号
国药准字H20020242
生产企业
浙江万联药业有限公司(国产)
适应症
本品主要用于治疗晚期乳腺癌和晚期子宫内膜癌，对肾癌、前列腺癌和卵巢癌有一定疗效。并可改善晚期肿癌患者的食欲和恶液质。
用法用量
?口服.一般剂量:160mg/次、每日一次.高剂量:160mg/次、每日2-4次.
不良反应
1.体重增加：为本品的常见副作用，且常伴有食欲增加。这种体重增加是由于体内脂肪和体细胞体积增加所致，而不一定伴有液体潴溜。对于癌症恶液质患者及体重下降、食欲减退的癌症病人，这种副作用常常是有益的。
2.血栓栓塞现象：罕见报道，包括血栓性静脉炎及肺动脉栓塞。
3.其它不良反应：偶有恶心、呕吐、水肿，子宫突破性出血可发生于约1～2%的病人。呼吸困难、心衰、高血压、脸潮红、情绪改变、柯兴式面容、肿瘤复发（伴或不伴有高钙血症）、高血糖、秃发、腕管综合证和皮疹为罕见。罕见轻度肾上腺功能减退，可能因本品的糖皮质激素样活性所致。
禁忌
对本品过敏者禁用。对伴有严重血栓性静脉炎、血栓栓塞性疾病、严重肝功能损害和因骨转移产生的高钙血症患者禁用。
注意事项
1.对接受本品治疗的患人应进行常规的密切监测。
2.对未控制的糖尿病及高血压患者需小心使用。
3.不主张用于乳腺癌的术后辅助治疗。
4.有血栓性静脉炎病史者慎用。
贮藏
遮光，密封保存。
规格
40mg*32粒
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.